NICHOLASMITSIADES, M.D.NICHOLAS MITSIADES, M.D.0.000000000000000.000000000000001781MITSIADES, M.D., NICHOLASAdjunct Associate Professorprns:coAuthorOfcoauthor ofprns:emailEncryptedemail addressprns:endDateend dateFaculty Rankprns:fullNamefull nameprns:grantAwardedBygrant awarded byprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:physicalNeighborOfphysical neighborprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:principalInvestigatorNameprincipal investigator nameprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:startDatestart dateprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:address1address line 1vivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provinceAgreementvivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipDepartmentDivisionGrantvivo:hasResearchArearesearch areasvivo:hasResearcherRoleresearch activitiesvivo:hrJobTitleHR job titleInformation Resourcevivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:personInPositionpositionsPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titleResearcher Rolevivo:researcherRoleOfresearcher role ofRolevivo:roleContributesTocontributes tovivo:sponsorAwardIdsponsor award idrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson25489091He B, Lanz RB, Fiskus W, Geng C, Yi P, Hartig SM, Rajapakshe K, Shou J, Wei L, Shah SS, Foley C, Chew SA, Eedunuri VK, Bedoya DJ, Feng Q, Minami T, Mitsiades CS, Frolov A, Weigel NL, Hilsenbeck SG, Rosen DG, Palzkill T, Ittmann MM, Song Y, Coarfa C, O'Malley BW, Mitsiades NProceedings of the National Academy of Sciences of the United States of AmericaGATA2 facilitates steroid receptor coactivator recruitment to the androgen receptor complex. Proc Natl Acad Sci U S A. 2014 Dec 23; 111(51):18261-6.Proc Natl Acad Sci U S A2014-12-08T00:00:002014GATA2 facilitates steroid receptor coactivator recruitment to the androgen receptor complex.Authorship 831021Authorship 838879Authorship 823576Authorship 967241Authorship 1070281Authorship 1118064Authorship 168661Authorship 21235Authorship 1616861325664849Dasgupta S, Putluri N, Long W, Zhang B, Wang J, Kaushik AK, Arnold JM, Bhowmik SK, Stashi E, Brennan CA, Rajapakshe K, Coarfa C, Mitsiades N, Ittmann MM, Chinnaiyan AM, Sreekumar A, O'Malley BWThe Journal of clinical investigationCoactivator SRC-2-dependent metabolic reprogramming mediates prostate cancer survival and metastasis. J Clin Invest. 2015 Mar 02; 125(3):1174-88.J Clin Invest2015-02-09T00:00:002015Coactivator SRC-2-dependent metabolic reprogramming mediates prostate cancer survival and metastasis.Authorship 382148Genitourinary Medical OncologyLeukemiaLymphoma-MyelomaRadiation OncologySystems BiologyMD AndersonJORGE ECORTESJORGE E CORTES8637CORTES, JORGE EProfessorHAGOP MKANTARJIANHAGOP M KANTARJIAN8501KANTARJIAN, HAGOP MProfessorGORDON BMILLSGORDON B MILLS8620MILLS, GORDON BProfessorCHRISTOPHER JLOGOTHETISCHRISTOPHER J LOGOTHETIS8480LOGOTHETIS, CHRISTOPHER JProfessorSEAN ERICMCGUIRESEAN ERIC MCGUIRE9271MCGUIRE, SEAN ERICAssociate ProfessorROBERTORLOWSKIROBERT ORLOWSKI9449ORLOWSKI, ROBERTProfessorAuthorship 467696Authorship 5173812Authorship 523871Authorship 53161Authorship 59245Authorship 725281Authorship 758981Authorship 805835Authorship 86911Authorship 910265Authorship 9382011One Baylor Plaza #100Houston, 77030TX26833126Nikolai BC, Lanz RB, York B, Dasgupta S, Mitsiades N, Creighton CJ, Tsimelzon A, Hilsenbeck SG, Lonard DM, Smith CL, O'Malley BWCancer researchHER2 Signaling Drives DNA Anabolism and Proliferation through SRC-3 Phosphorylation and E2F1-Regulated Genes. Cancer Res. 2016 Mar 15; 76(6):1463-75.Cancer Res2016-02-01T00:00:002016HER2 Signaling Drives DNA Anabolism and Proliferation through SRC-3 Phosphorylation and E2F1-Regulated Genes.Authorship 3019422Authorship 3053991226066330Eedunuri VK, Rajapakshe K, Fiskus W, Geng C, Chew SA, Foley C, Shah SS, Shou J, Mohamed JS, Coarfa C, O'Malley BW, Mitsiades NMolecular endocrinology (Baltimore, Md.)miR-137 Targets p160 Steroid Receptor Coactivators SRC1, SRC2, and SRC3 and Inhibits Cell Proliferation. Mol Endocrinol. 2015 Aug; 29(8):1170-83.Mol Endocrinol2015-06-12T00:00:002015miR-137 Targets p160 Steroid Receptor Coactivators SRC1, SRC2, and SRC3 and Inhibits Cell Proliferation.26768236Fiskus W, Mitsiades NAnnual review of medicineB-Raf Inhibition in the Clinic: Present and Future. Annu Rev Med. 2016; 67:29-43.Annu Rev Med2016-01-01T00:00:002016B-Raf Inhibition in the Clinic: Present and Future.11924912Treon SP, Pilarski LM, Belch AR, Kelliher A, Preffer FI, Shima Y, Mitsiades CS, Mitsiades NS, Szczepek AJ, Ellman L, Harmon D, Grossbard ML, Anderson KCJournal of immunotherapy (Hagerstown, Md. : 1997)CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications. J Immunother. 2002 Jan-Feb; 25(1):72-81.J Immunother2002-01-01T00:00:002002CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications.12036884Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, Munshi NC, Treon SP, Anderson KCBloodApoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood. 2002 Jun 15; 99(12):4525-30.Blood2002-06-15T00:00:002002Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications.12173037Mitsiades CS, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, Chauhan D, Hideshima T, Treon SP, Munshi NC, Richardson PG, Anderson KCOncogeneActivation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene. 2002 Aug 22; 21(37):5673-83.Oncogene2002-08-22T00:00:002002Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications.12475915Joussen AM, Poulaki V, Mitsiades N, Cai WY, Suzuma I, Pak J, Ju ST, Rook SL, Esser P, Mitsiades CS, Kirchhof B, Adamis AP, Aiello LPFASEB journal : official publication of the Federation of American Societies for Experimental BiologySuppression of Fas-FasL-induced endothelial cell apoptosis prevents diabetic blood-retinal barrier breakdown in a model of streptozotocin-induced diabetes. FASEB J. 2003 Jan; 17(1):76-8.FASEB J2002-11-15T00:00:002002Suppression of Fas-FasL-induced endothelial cell apoptosis prevents diabetic blood-retinal barrier breakdown in a model of streptozotocin-induced diabetes.12480690Chauhan D, Li G, Auclair D, Hideshima T, Richardson P, Podar K, Mitsiades N, Mitsiades C, Li C, Kim RS, Munshi N, Chen LB, Wong W, Anderson KCBloodIdentification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays. Blood. 2003 May 01; 101(9):3606-14.Blood2002-12-12T00:00:002002Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays.12531799Mitsiades N, Mitsiades CS, Richardson PG, McMullan C, Poulaki V, Fanourakis G, Schlossman R, Chauhan D, Munshi NC, Hideshima T, Richon VM, Marks PA, Anderson KCBloodMolecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood. 2003 May 15; 101(10):4055-62.Blood2003-01-16T00:00:002003Molecular sequelae of histone deacetylase inhibition in human malignant B cells.12720159Mitsiades CS, Mitsiades N, Richardson PG, Treon SP, Anderson KCSeminars in oncologyNovel biologically based therapies for Waldenstrom's macroglobulinemia. Semin Oncol. 2003 Apr; 30(2):309-12.Semin Oncol2003-04-01T00:00:002003Novel biologically based therapies for Waldenstrom's macroglobulinemia.12947006Davies FE, Dring AM, Li C, Rawstron AC, Shammas MA, O'Connor SM, Fenton JA, Hideshima T, Chauhan D, Tai IT, Robinson E, Auclair D, Rees K, Gonzalez D, Ashcroft AJ, Dasgupta R, Mitsiades C, Mitsiades N, Chen LB, Wong WH, Munshi NC, Morgan GJ, Anderson KCBloodInsights into the multistep transformation of MGUS to myeloma using microarray expression analysis. Blood. 2003 Dec 15; 102(13):4504-11.Blood2003-08-28T00:00:002003Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis.13679868Chauhan D, Li G, Sattler M, Podar K, Mitsiades C, Mitsiades N, Munshi N, Hideshima T, Anderson KCOncogeneSuperoxide-dependent and -independent mitochondrial signaling during apoptosis in multiple myeloma cells. Oncogene. 2003 Sep 18; 22(40):6296-300.Oncogene2003-09-18T00:00:002003Superoxide-dependent and -independent mitochondrial signaling during apoptosis in multiple myeloma cells.14557495Mitsiades CS, Sykoutri D, McMullan C, Poulaki V, Mitsiades NThe Journal of clinical endocrinology and metabolismEffect of imatinib mesylate (Gleevec) on anaplastic thyroid carcinoma cell lines. J Clin Endocrinol Metab. 2003 Oct; 88(10):5043-4; author reply 5044.J Clin Endocrinol Metab2003-10-01T00:00:002003Effect of imatinib mesylate (Gleevec) on anaplastic thyroid carcinoma cell lines.14583463Mitsiades CS, Mitsiades NS, Bronson RT, Chauhan D, Munshi N, Treon SP, Maxwell CA, Pilarski L, Hideshima T, Hoffman RM, Anderson KCCancer researchFluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications. Cancer Res. 2003 Oct 15; 63(20):6689-96.Cancer Res2003-10-15T00:00:002003Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications.14602779Poulaki V, Mitsiades CS, McMullan C, Sykoutri D, Fanourakis G, Kotoula V, Tseleni-Balafouta S, Koutras DA, Mitsiades NThe Journal of clinical endocrinology and metabolismRegulation of vascular endothelial growth factor expression by insulin-like growth factor I in thyroid carcinomas. J Clin Endocrinol Metab. 2003 Nov; 88(11):5392-8.J Clin Endocrinol Metab2003-11-01T00:00:002003Regulation of vascular endothelial growth factor expression by insulin-like growth factor I in thyroid carcinomas.14695887Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Hideshima T, Akiyama M, Chauhan D, Munshi N, Gu X, Bailey C, Joseph M, Libermann TA, Richon VM, Marks PA, Anderson KCProceedings of the National Academy of Sciences of the United States of AmericaTranscriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci U S A. 2004 Jan 13; 101(2):540-5.Proc Natl Acad Sci U S A2003-12-26T00:00:002003Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications.15134532Mitsiades CS, Mitsiades N, Koutsilieris MCurrent cancer drug targetsThe Akt pathway: molecular targets for anti-cancer drug development. Curr Cancer Drug Targets. 2004 May; 4(3):235-56.Curr Cancer Drug Targets2004-05-01T00:00:002004The Akt pathway: molecular targets for anti-cancer drug development.11877293Mitsiades N, Mitsiades CS, Poulaki V, Anderson KC, Treon SPBloodIntracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells. Blood. 2002 Mar 15; 99(6):2162-71.Blood2002-03-15T00:00:002002Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells.12010810Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, Munshi N, Treon SP, Anderson KCBloodBiologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood. 2002 Jun 01; 99(11):4079-86.Blood2002-06-01T00:00:002002Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications.15623796Poulaki V, Mitsiades CS, McMullan C, Fanourakis G, Negri J, Goudopoulou A, Halikias IX, Voutsinas G, Tseleni-Balafouta S, Miller JW, Mitsiades NInvestigative ophthalmology & visual scienceHuman retinoblastoma cells are resistant to apoptosis induced by death receptors: role of caspase-8 gene silencing. Invest Ophthalmol Vis Sci. 2005 Jan; 46(1):358-66.Invest Ophthalmol Vis Sci2005-01-01T00:00:002005Human retinoblastoma cells are resistant to apoptosis induced by death receptors: role of caspase-8 gene silencing.74Professor10Assistant Professor14Associate Professor3Adjunct Associate Professor78Professor Emeritus47Distinguished Service ProfessorWARREN CFISKUSWARREN C FISKUS11958FISKUS, WARREN CAssistant Professor12482878Podar K, Tai YT, Cole CE, Hideshima T, Sattler M, Hamblin A, Mitsiades N, Schlossman RL, Davies FE, Morgan GJ, Munshi NC, Chauhan D, Anderson KCThe Journal of biological chemistryEssential role of caveolae in interleukin-6- and insulin-like growth factor I-triggered Akt-1-mediated survival of multiple myeloma cells. J Biol Chem. 2003 Feb 21; 278(8):5794-801.J Biol Chem2002-12-12T00:00:002002Essential role of caveolae in interleukin-6- and insulin-like growth factor I-triggered Akt-1-mediated survival of multiple myeloma cells.27194471Kaushik AK, Shojaie A, Panzitt K, Sonavane R, Venghatakrishnan H, Manikkam M, Zaslavsky A, Putluri V, Vasu VT, Zhang Y, Khan AS, Lloyd S, Szafran AT, Dasgupta S, Bader DA, Stossi F, Li H, Samanta S, Cao X, Tsouko E, Huang S, Frigo DE, Chan L, Edwards DP, Kaipparettu BA, Mitsiades N, Weigel NL, Mancini M, McGuire SE, Mehra R, Ittmann MM, Chinnaiyan AM, Putluri N, Palapattu GS, Michailidis G, Sreekumar ANature communicationsInhibition of the hexosamine biosynthetic pathway promotes castration-resistant prostate cancer. Nat Commun. 2016 05 19; 7:11612.Nat Commun2016-05-19T00:00:002016Inhibition of the hexosamine biosynthetic pathway promotes castration-resistant prostate cancer.12517770Akiyama M, Hideshima T, Hayashi T, Tai YT, Mitsiades CS, Mitsiades N, Chauhan D, Richardson P, Munshi NC, Anderson KCCancer researchNuclear factor-kappaB p65 mediates tumor necrosis factor alpha-induced nuclear translocation of telomerase reverse transcriptase protein. Cancer Res. 2003 Jan 01; 63(1):18-21.Cancer Res2003-01-01T00:00:002003Nuclear factor-kappaB p65 mediates tumor necrosis factor alpha-induced nuclear translocation of telomerase reverse transcriptase protein.16001954Mitsiades CS, Mitsiades N, Hideshima T, Richardson PG, Anderson KCExpert review of anticancer therapyProteasome inhibition as a therapeutic strategy for hematologic malignancies. Expert Rev Anticancer Ther. 2005 Jun; 5(3):465-76.Expert Rev Anticancer Ther2005-06-01T00:00:002005Proteasome inhibition as a therapeutic strategy for hematologic malignancies.16001956Mitsiades CS, Mitsiades NExpert review of anticancer therapyTreatment of hematologic malignancies and solid tumors by inhibiting IGF receptor signaling. Expert Rev Anticancer Ther. 2005 Jun; 5(3):487-99.Expert Rev Anticancer Ther2005-06-01T00:00:002005Treatment of hematologic malignancies and solid tumors by inhibiting IGF receptor signaling.12720127Mitsiades CS, Mitsiades N, Treon SP, Anderson KCSeminars in oncologyProteomic analyses in Waldenstrom's macroglobulinemia and other plasma cell dyscrasias. Semin Oncol. 2003 Apr; 30(2):156-60.Semin Oncol2003-04-01T00:00:002003Proteomic analyses in Waldenstrom's macroglobulinemia and other plasma cell dyscrasias.12720146Treon SP, Kelliher A, Keele B, Frankel S, Emmanouilides C, Kimby E, Schlossman R, Mitsiades N, Mitsiades C, Preffer F, Anderson KCSeminars in oncologyExpression of serotherapy target antigens in Waldenstrom's macroglobulinemia: therapeutic applications and considerations. Semin Oncol. 2003 Apr; 30(2):248-52.Semin Oncol2003-04-01T00:00:002003Expression of serotherapy target antigens in Waldenstrom's macroglobulinemia: therapeutic applications and considerations.16250907Mitsiades CS, Mitsiades N, Hideshima T, Richardson PG, Anderson KCEssays in biochemistryProteasome inhibitors as therapeutics. Essays Biochem. 2005; 41:205-18.Essays Biochem2005-01-01T00:00:002005Proteasome inhibitors as therapeutics.Medicine-Epidemiology & Populat SciAuthorship 3205012Authorship 3207345Authorship 323462626728473Foley C, Mitsiades NHormones & cancerMoving Beyond the Androgen Receptor (AR): Targeting AR-Interacting Proteins to Treat Prostate Cancer. Horm Cancer. 2016 Apr; 7(2):84-103.Horm Cancer2016-01-04T00:00:002016Moving Beyond the Androgen Receptor (AR): Targeting AR-Interacting Proteins to Treat Prostate Cancer.16822827Mitsiades CS, Kotoula V, Poulaki V, Sozopoulos E, Negri J, Charalambous E, Fanourakis G, Voutsinas G, Tseleni-Balafouta S, Mitsiades NThe Journal of clinical endocrinology and metabolismEpidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: mutational and functional analysis. J Clin Endocrinol Metab. 2006 Sep; 91(9):3662-6.J Clin Endocrinol Metab2006-07-05T00:00:002006Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: mutational and functional analysis.17192291K?rner A, Pazaitou-Panayiotou K, Kelesidis T, Kelesidis I, Williams CJ, Kaprara A, Bullen J, Neuwirth A, Tseleni S, Mitsiades N, Kiess W, Mantzoros CSThe Journal of clinical endocrinology and metabolismTotal and high-molecular-weight adiponectin in breast cancer: in vitro and in vivo studies. J Clin Endocrinol Metab. 2007 Mar; 92(3):1041-8.J Clin Endocrinol Metab2006-12-27T00:00:002006Total and high-molecular-weight adiponectin in breast cancer: in vitro and in vivo studies.17363500Mitsiades CS, Negri J, McMullan C, McMillin DW, Sozopoulos E, Fanourakis G, Voutsinas G, Tseleni-Balafouta S, Poulaki V, Batt D, Mitsiades NMolecular cancer therapeuticsTargeting BRAFV600E in thyroid carcinoma: therapeutic implications. Mol Cancer Ther. 2007 Mar; 6(3):1070-8.Mol Cancer Ther2007-03-01T00:00:002007Targeting BRAFV600E in thyroid carcinoma: therapeutic implications.15050914Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Akiyama M, Hideshima T, Chauhan D, Joseph M, Libermann TA, Garc?a-Echeverr?a C, Pearson MA, Hofmann F, Anderson KC, Kung ALCancer cellInhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell. 2004 Mar; 5(3):221-30.Cancer Cell2004-03-01T00:00:002004Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors.12665525Chauhan D, Li G, Hideshima T, Podar K, Mitsiades C, Mitsiades N, Munshi N, Kharbanda S, Anderson KCThe Journal of biological chemistryJNK-dependent release of mitochondrial protein, Smac, during apoptosis in multiple myeloma (MM) cells. J Biol Chem. 2003 May 16; 278(20):17593-6.J Biol Chem2003-03-28T00:00:002003JNK-dependent release of mitochondrial protein, Smac, during apoptosis in multiple myeloma (MM) cells.12816865Catley L, Weisberg E, Tai YT, Atadja P, Remiszewski S, Hideshima T, Mitsiades N, Shringarpure R, LeBlanc R, Chauhan D, Munshi NC, Schlossman R, Richardson P, Griffin J, Anderson KCBloodNVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood. 2003 Oct 01; 102(7):2615-22.Blood2003-06-19T00:00:002003NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma.15242253Mitsiades CS, Mitsiades NCurrent opinion in investigational drugs (London, England : 2000)CC-5013 (Celgene). Curr Opin Investig Drugs. 2004 Jun; 5(6):635-47.Curr Opin Investig Drugs2004-06-01T00:00:002004CC-5013 (Celgene).15277220Poulaki V, Joussen AM, Mitsiades N, Mitsiades CS, Iliaki EF, Adamis APThe American journal of pathologyInsulin-like growth factor-I plays a pathogenetic role in diabetic retinopathy. Am J Pathol. 2004 Aug; 165(2):457-69.Am J Pathol2004-08-01T00:00:002004Insulin-like growth factor-I plays a pathogenetic role in diabetic retinopathy.18310295Williams CJ, Mitsiades N, Sozopoulos E, Hsi A, Wolk A, Nifli AP, Tseleni-Balafouta S, Mantzoros CSEndocrine-related cancerAdiponectin receptor expression is elevated in colorectal carcinomas but not in gastrointestinal stromal tumors. Endocr Relat Cancer. 2008 Mar; 15(1):289-99.Endocr Relat Cancer2008-03-01T00:00:002008Adiponectin receptor expression is elevated in colorectal carcinomas but not in gastrointestinal stromal tumors.12969976Munshi NC, Hideshima T, Carrasco D, Shammas M, Auclair D, Davies F, Mitsiades N, Mitsiades C, Kim RS, Li C, Rajkumar SV, Fonseca R, Bergsagel L, Chauhan D, Anderson KCBloodIdentification of genes modulated in multiple myeloma using genetically identical twin samples. Blood. 2004 Mar 01; 103(5):1799-806.Blood2003-09-11T00:00:002003Identification of genes modulated in multiple myeloma using genetically identical twin samples.15542427Mitsiades CS, Mitsiades N, Munshi NC, Anderson KCCancer cellFocus on multiple myeloma. Cancer Cell. 2004 Nov; 6(5):439-44.Cancer Cell2004-11-01T00:00:002004Focus on multiple myeloma.14512311LeBlanc R, Hideshima T, Catley LP, Shringarpure R, Burger R, Mitsiades N, Mitsiades C, Cheema P, Chauhan D, Richardson PG, Anderson KC, Munshi NCBloodImmunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood. 2004 Mar 01; 103(5):1787-90.Blood2003-09-25T00:00:002003Immunomodulatory drug costimulates T cells via the B7-CD28 pathway.19051043Dalamaga M, Migdalis I, Fargnoli JL, Papadavid E, Bloom E, Mitsiades N, Karmaniolas K, Pelecanos N, Tseleni-Balafouta S, Dionyssiou-Asteriou A, Mantzoros CSCancer causes & control : CCCPancreatic cancer expresses adiponectin receptors and is associated with hypoleptinemia and hyperadiponectinemia: a case-control study. Cancer Causes Control. 2009 Jul; 20(5):625-33.Cancer Causes Control2008-12-03T00:00:002008Pancreatic cancer expresses adiponectin receptors and is associated with hypoleptinemia and hyperadiponectinemia: a case-control study.14627979Hideshima T, Chauhan D, Hayashi T, Akiyama M, Mitsiades N, Mitsiades C, Podar K, Munshi NC, Richardson PG, Anderson KCOncogeneProteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma. Oncogene. 2003 Nov 20; 22(52):8386-93.Oncogene2003-11-20T00:00:002003Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma.15039217Poulaki V, Mitsiades N, Kruse FE, Radetzky S, Iliaki E, Kirchhof B, Joussen AMThe American journal of pathologyActivin a in the regulation of corneal neovascularization and vascular endothelial growth factor expression. Am J Pathol. 2004 Apr; 164(4):1293-302.Am J Pathol2004-04-01T00:00:002004Activin a in the regulation of corneal neovascularization and vascular endothelial growth factor expression.15897598Mitsiades CS, Poulaki V, McMullan C, Negri J, Fanourakis G, Goudopoulou A, Richon VM, Marks PA, Mitsiades NClinical cancer research : an official journal of the American Association for Cancer ResearchNovel histone deacetylase inhibitors in the treatment of thyroid cancer. Clin Cancer Res. 2005 May 15; 11(10):3958-65.Clin Cancer Res2005-05-15T00:00:002005Novel histone deacetylase inhibitors in the treatment of thyroid cancer.16234364Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Kung AL, Davies FE, Morgan G, Akiyama M, Shringarpure R, Munshi NC, Richardson PG, Hideshima T, Chauhan D, Gu X, Bailey C, Joseph M, Libermann TA, Rosen NS, Anderson KCBloodAntimyeloma activity of heat shock protein-90 inhibition. Blood. 2006 Feb 01; 107(3):1092-100.Blood2005-10-18T00:00:002005Antimyeloma activity of heat shock protein-90 inhibition.21937620Mitsiades N, Pazaitou-Panayiotou K, Aronis KN, Moon HS, Chamberland JP, Liu X, Diakopoulos KN, Kyttaris V, Panagiotou V, Mylvaganam G, Tseleni-Balafouta S, Mantzoros CSThe Journal of clinical endocrinology and metabolismCirculating adiponectin is inversely associated with risk of thyroid cancer: in vivo and in vitro studies. J Clin Endocrinol Metab. 2011 Dec; 96(12):E2023-8.J Clin Endocrinol Metab2011-09-21T00:00:002011Circulating adiponectin is inversely associated with risk of thyroid cancer: in vivo and in vitro studies.16765041Mitsiades CS, Mitsiades NS, Munshi NC, Richardson PG, Anderson KCEuropean journal of cancer (Oxford, England : 1990)The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions. Eur J Cancer. 2006 Jul; 42(11):1564-73.Eur J Cancer2006-06-09T00:00:002006The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions.17032924Chauhan D, Neri P, Velankar M, Podar K, Hideshima T, Fulciniti M, Tassone P, Raje N, Mitsiades C, Mitsiades N, Richardson P, Zawel L, Tran M, Munshi N, Anderson KCBloodTargeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM). Blood. 2007 Feb 01; 109(3):1220-7.Blood2006-10-10T00:00:002006Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM).16166312Chauhan D, Li G, Podar K, Hideshima T, Neri P, He D, Mitsiades N, Richardson P, Chang Y, Schindler J, Carver B, Anderson KCCancer researchA novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells. Cancer Res. 2005 Sep 15; 65(18):8350-8.Cancer Res2005-09-15T00:00:002005A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.17073596Mitsiades CS, Mitsiades N, Hideshima T, Richardson PG, Anderson KCCurrent drug targetsProteasome inhibition as a new therapeutic principle in hematological malignancies. Curr Drug Targets. 2006 Oct; 7(10):1341-7.Curr Drug Targets2006-10-01T00:00:002006Proteasome inhibition as a new therapeutic principle in hematological malignancies.22971343Mitsiades N, Sung CC, Schultz N, Danila DC, He B, Eedunuri VK, Fleisher M, Sander C, Sawyers CL, Scher HICancer researchDistinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors. Cancer Res. 2012 Dec 01; 72(23):6142-52.Cancer Res2012-09-12T00:00:002012Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors.17301264Michalakis K, Williams CJ, Mitsiades N, Blakeman J, Balafouta-Tselenis S, Giannopoulos A, Mantzoros CSCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive OncologySerum adiponectin concentrations and tissue expression of adiponectin receptors are reduced in patients with prostate cancer: a case control study. Cancer Epidemiol Biomarkers Prev. 2007 Feb; 16(2):308-13.Cancer Epidemiol Biomarkers Prev2007-02-01T00:00:002007Serum adiponectin concentrations and tissue expression of adiponectin receptors are reduced in patients with prostate cancer: a case control study.17433850Wadhera A, Maverakis E, Mitsiades N, Lara PN, Fung MA, Lynch PJJournal of the American Academy of DermatologyThymoma-associated multiorgan autoimmunity: a graft-versus-host-like disease. J Am Acad Dermatol. 2007 Oct; 57(4):683-9.J Am Acad Dermatol2007-04-16T00:00:002007Thymoma-associated multiorgan autoimmunity: a graft-versus-host-like disease.16778096Mitsiades CS, Poulaki V, Fanourakis G, Sozopoulos E, McMillin D, Wen Z, Voutsinas G, Tseleni-Balafouta S, Mitsiades NClinical cancer research : an official journal of the American Association for Cancer ResearchFas signaling in thyroid carcinomas is diverted from apoptosis to proliferation. Clin Cancer Res. 2006 Jun 15; 12(12):3705-12.Clin Cancer Res2006-06-15T00:00:002006Fas signaling in thyroid carcinomas is diverted from apoptosis to proliferation.17848408Mitsiades CS, Hayden P, Kotoula V, McMillin DW, McMullan C, Negri J, Delmore JE, Poulaki V, Mitsiades NThe Journal of clinical endocrinology and metabolismBcl-2 overexpression in thyroid carcinoma cells increases sensitivity to Bcl-2 homology 3 domain inhibition. J Clin Endocrinol Metab. 2007 Dec; 92(12):4845-52.J Clin Endocrinol Metab2007-09-11T00:00:002007Bcl-2 overexpression in thyroid carcinoma cells increases sensitivity to Bcl-2 homology 3 domain inhibition.17400913Poulaki V, Iliaki E, Mitsiades N, Mitsiades CS, Paulus YN, Bula DV, Gragoudas ES, Miller JWFASEB journal : official publication of the Federation of American Societies for Experimental BiologyInhibition of Hsp90 attenuates inflammation in endotoxin-induced uveitis. FASEB J. 2007 Jul; 21(9):2113-23.FASEB J2007-03-30T00:00:002007Inhibition of Hsp90 attenuates inflammation in endotoxin-induced uveitis.18593922Mitsiades CS, Ocio EM, Pandiella A, Maiso P, Gajate C, Garayoa M, Vilanova D, Montero JC, Mitsiades N, McMullan CJ, Munshi NC, Hideshima T, Chauhan D, Aviles P, Otero G, Faircloth G, Mateos MV, Richardson PG, Mollinedo F, San-Miguel JF, Anderson KCCancer researchAplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo. Cancer Res. 2008 Jul 01; 68(13):5216-25.Cancer Res2008-07-01T00:00:002008Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo.27374105Xiao L, Feng Q, Zhang Z, Wang F, Lydon JP, Ittmann MM, Xin L, Mitsiades N, He BOncotargetThe essential role of GATA transcription factors in adult murine prostate. Oncotarget. 2016 Jul 26; 7(30):47891-47903.Oncotarget2016-07-26T00:00:002016The essential role of GATA transcription factors in adult murine prostate.Authorship 605381819027461Mitsiades N, Correa D, Gross CP, Hurria A, Slovin SFSeminars in oncologyCognitive effects of hormonal therapy in older adults. Semin Oncol. 2008 Dec; 35(6):569-81.Semin Oncol2008-12-01T00:00:002008Cognitive effects of hormonal therapy in older adults.19190079Kotoula V, Sozopoulos E, Litsiou H, Fanourakis G, Koletsa T, Voutsinas G, Tseleni-Balafouta S, Mitsiades CS, Wellmann A, Mitsiades NEndocrine-related cancerMutational analysis of the BRAF, RAS and EGFR genes in human adrenocortical carcinomas. Endocr Relat Cancer. 2009 Jun; 16(2):565-72.Endocr Relat Cancer2009-02-03T00:00:002009Mutational analysis of the BRAF, RAS and EGFR genes in human adrenocortical carcinomas.19387079Poulaki V, Mitsiades CS, Kotoula V, Negri J, McMullan C, Miller JW, Marks PA, Mitsiades NInvestigative ophthalmology & visual scienceMolecular sequelae of histone deacetylase inhibition in human retinoblastoma cell lines: clinical implications. Invest Ophthalmol Vis Sci. 2009 Sep; 50(9):4072-9.Invest Ophthalmol Vis Sci2009-04-22T00:00:002009Molecular sequelae of histone deacetylase inhibition in human retinoblastoma cell lines: clinical implications.19553613Iliaki E, Poulaki V, Mitsiades N, Mitsiades CS, Miller JW, Gragoudas ESInvestigative ophthalmology & visual scienceRole of alpha 4 integrin (CD49d) in the pathogenesis of diabetic retinopathy. Invest Ophthalmol Vis Sci. 2009 Oct; 50(10):4898-904.Invest Ophthalmol Vis Sci2009-06-24T00:00:002009Role of alpha 4 integrin (CD49d) in the pathogenesis of diabetic retinopathy.Authorship 652667627780719Wu F, Dai X, Gan W, Wan L, Li M, Mitsiades N, Wei W, Ding Q, Zhang JCancer lettersProstate cancer-associated mutation in SPOP impairs its ability to target Cdc20 for poly-ubiquitination and degradation. Cancer Lett. 2017 01 28; 385:207-214.Cancer Lett2016-10-22T00:00:002016Prostate cancer-associated mutation in SPOP impairs its ability to target Cdc20 for poly-ubiquitination and degradation.19934289Ooi MG, Hayden PJ, Kotoula V, McMillin DW, Charalambous E, Daskalaki E, Raje NS, Munshi NC, Chauhan D, Hideshima T, Buon L, Clynes M, O'Gorman P, Richardson PG, Mitsiades CS, Anderson KC, Mitsiades NClinical cancer research : an official journal of the American Association for Cancer ResearchInteractions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib. Clin Cancer Res. 2009 Dec 01; 15(23):7153-60.Clin Cancer Res2009-11-24T00:00:002009Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib.20036106Takada Y, Ono Y, Saegusa J, Sagusa J, Mitsiades C, Mitsiades N, Tsai J, He Y, Maningding E, Coleman A, Ramirez-Maverakis D, Rodrigues R, Rodriquez R, Takada Y, Maverakis EJournal of autoimmunityA T cell-binding fragment of fibrinogen can prevent autoimmunity. J Autoimmun. 2010 Jun; 34(4):453-9.J Autoimmun2009-12-24T00:00:002009A T cell-binding fragment of fibrinogen can prevent autoimmunity.20579941Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N, Landers T, Dolgalev I, Major JE, Wilson M, Socci ND, Lash AE, Heguy A, Eastham JA, Scher HI, Reuter VE, Scardino PT, Sander C, Sawyers CL, Gerald WLCancer cellIntegrative genomic profiling of human prostate cancer. Cancer Cell. 2010 Jul 13; 18(1):11-22.Cancer Cell2010-06-24T00:00:002010Integrative genomic profiling of human prostate cancer.20228816McMillin DW, Delmore J, Weisberg E, Negri JM, Geer DC, Klippel S, Mitsiades N, Schlossman RL, Munshi NC, Kung AL, Griffin JD, Richardson PG, Anderson KC, Mitsiades CSNature medicineTumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat Med. 2010 Apr; 16(4):483-9.Nat Med2010-03-14T00:00:002010Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity.Authorship 101129122149426Bedoya DJ, Mitsiades NExpert review of anticancer therapyAbiraterone acetate, a first-in-class CYP17 inhibitor, establishes a new treatment paradigm in castration-resistant prostate cancer. Expert Rev Anticancer Ther. 2012 Jan; 12(1):1-3.Expert Rev Anticancer Ther2012-01-01T00:00:002012Abiraterone acetate, a first-in-class CYP17 inhibitor, establishes a new treatment paradigm in castration-resistant prostate cancer.Authorship 1015731023319868Bedoya DJ, Mitsiades NOncoTargets and therapyClinical appraisal of abiraterone in the treatment of metastatic prostatic cancer: patient considerations, novel opportunities, and future directions. Onco Targets Ther. 2013; 6:9-18.Onco Targets Ther2013-01-03T00:00:002013Clinical appraisal of abiraterone in the treatment of metastatic prostatic cancer: patient considerations, novel opportunities, and future directions.23559371Geng C, He B, Xu L, Barbieri CE, Eedunuri VK, Chew SA, Zimmermann M, Bond R, Shou J, Li C, Blattner M, Lonard DM, Demichelis F, Coarfa C, Rubin MA, Zhou P, O'Malley BW, Mitsiades NProceedings of the National Academy of Sciences of the United States of AmericaProstate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover. Proc Natl Acad Sci U S A. 2013 Apr 23; 110(17):6997-7002.Proc Natl Acad Sci U S A2013-04-04T00:00:002013Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover.Authorship 868699528358937Flaig TW, Plets M, Hussain MHA, Agarwal N, Mitsiades N, Deshpande HA, Vaishampayan UN, Thompson IMJAMA oncologyAbiraterone Acetate for Metastatic Prostate Cancer in Patients With Suboptimal Biochemical Response to Hormone Induction. JAMA Oncol. 2017 Nov 09; 3(11):e170231.JAMA Oncol2017-11-09T00:00:002017Abiraterone Acetate for Metastatic Prostate Cancer in Patients With Suboptimal Biochemical Response to Hormone Induction.11872748Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, Munshi N, Dang L, Castro A, Palombella V, Adams J, Anderson KCThe Journal of biological chemistryNF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem. 2002 May 10; 277(19):16639-47.J Biol Chem2002-02-28T00:00:002002NF-kappa B as a therapeutic target in multiple myeloma.12097303Akiyama M, Hideshima T, Hayashi T, Tai YT, Mitsiades CS, Mitsiades N, Chauhan D, Richardson P, Munshi NC, Anderson KCCancer researchCytokines modulate telomerase activity in a human multiple myeloma cell line. Cancer Res. 2002 07 01; 62(13):3876-82.Cancer Res2002-07-01T00:00:002002Cytokines modulate telomerase activity in a human multiple myeloma cell line.12135668Gupta D, Podar K, Tai YT, Lin B, Hideshima T, Akiyama M, LeBlanc R, Catley L, Mitsiades N, Mitsiades C, Chauhan D, Munshi NC, Anderson KCExperimental hematologybeta-lapachone, a novel plant product, overcomes drug resistance in human multiple myeloma cells. Exp Hematol. 2002 Jul; 30(7):711-20.Exp Hematol2002-07-01T00:00:002002beta-lapachone, a novel plant product, overcomes drug resistance in human multiple myeloma cells.12163389Poulaki V, Mitsiades CS, Kotoula V, Tseleni-Balafouta S, Ashkenazi A, Koutras DA, Mitsiades NThe American journal of pathologyRegulation of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in thyroid carcinoma cells. Am J Pathol. 2002 Aug; 161(2):643-54.Am J Pathol2002-08-01T00:00:002002Regulation of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in thyroid carcinoma cells.12466137Poulaki V, Mitsiades CS, Joussen AM, Lappas A, Kirchhof B, Mitsiades NThe American journal of pathologyConstitutive nuclear factor-kappaB activity is crucial for human retinoblastoma cell viability. Am J Pathol. 2002 12; 161(6):2229-40.Am J Pathol2002-12-01T00:00:002002Constitutive nuclear factor-kappaB activity is crucial for human retinoblastoma cell viability.12506063Joussen AM, Poulaki V, Mitsiades N, Stechschulte SU, Kirchhof B, Dartt DA, Fong GH, Rudge J, Wiegand SJ, Yancopoulos GD, Adamis APInvestigative ophthalmology & visual scienceVEGF-dependent conjunctivalization of the corneal surface. Invest Ophthalmol Vis Sci. 2003 Jan; 44(1):117-23.Invest Ophthalmol Vis Sci2003-01-01T00:00:002003VEGF-dependent conjunctivalization of the corneal surface.12727428Mitsiades CS, Mitsiades NLancet (London, England)P2X7 polymorphism and chronic lymphocytic leukaemia. Lancet. 2003 Apr 26; 361(9367):1478; author reply 1478-9.Lancet2003-04-26T00:00:002003P2X7 polymorphism and chronic lymphocytic leukaemia.12855565Chauhan D, Li G, Hideshima T, Podar K, Mitsiades C, Mitsiades N, Catley L, Tai YT, Hayashi T, Shringarpure R, Burger R, Munshi N, Ohtake Y, Saxena S, Anderson KCBloodHsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance. Blood. 2003 Nov 01; 102(9):3379-86.Blood2003-07-10T00:00:002003Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance.14522909Tai YT, Podar K, Catley L, Tseng YH, Akiyama M, Shringarpure R, Burger R, Hideshima T, Chauhan D, Mitsiades N, Richardson P, Munshi NC, Kahn CR, Mitsiades C, Anderson KCCancer researchInsulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling. Cancer Res. 2003 09 15; 63(18):5850-8.Cancer Res2003-09-15T00:00:002003Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling.14679006Hideshima T, Chauhan D, Hayashi T, Podar K, Akiyama M, Mitsiades C, MItsiades N, Gong B, Bonham L, de Vries P, Munshi N, Richardson PG, Singer JW, Anderson KCCancer researchAntitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma. Cancer Res. 2003 Dec 01; 63(23):8428-36.Cancer Res2003-12-01T00:00:002003Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma.15812903Mitsiades CS, Mitsiades NThyroid : official journal of the American Thyroid AssociationThyroid carcinoma cells and Fas-mediated apoptosis. Thyroid. 2005 Feb; 15(2):178-9.Thyroid2005-02-01T00:00:002005Thyroid carcinoma cells and Fas-mediated apoptosis.16849420Mitsiades CS, McMillin D, Kotoula V, Poulaki V, McMullan C, Negri J, Fanourakis G, Tseleni-Balafouta S, Ain KB, Mitsiades NThe Journal of clinical endocrinology and metabolismAntitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro. J Clin Endocrinol Metab. 2006 Oct; 91(10):4013-21.J Clin Endocrinol Metab2006-07-18T00:00:002006Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro.17546631Mitsiades CS, Mitsiades NS, Richardson PG, Munshi NC, Anderson KCJournal of cellular biochemistryMultiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment. J Cell Biochem. 2007 Jul 01; 101(4):950-68.J Cell Biochem2007-07-01T00:00:002007Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment.17898295Poulaki V, Mitsiades CS, Kotoula V, Negri J, McMillin D, Miller JW, Mitsiades NInvestigative ophthalmology & visual scienceThe proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro. Invest Ophthalmol Vis Sci. 2007 Oct; 48(10):4706-19.Invest Ophthalmol Vis Sci2007-10-01T00:00:002007The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro.18424891Petridou ET, Mitsiades N, Gialamas S, Angelopoulos M, Skalkidou A, Dessypris N, Hsi A, Lazaris N, Polyzos A, Syrigos C, Brennan AM, Tseleni-Balafouta S, Mantzoros CSOncologyCirculating adiponectin levels and expression of adiponectin receptors in relation to lung cancer: two case-control studies. Oncology. 2007; 73(3-4):261-9.Oncology2008-04-17T00:00:002008Circulating adiponectin levels and expression of adiponectin receptors in relation to lung cancer: two case-control studies.19041825Fagin JA, Mitsiades NBest practice & research. Clinical endocrinology & metabolismMolecular pathology of thyroid cancer: diagnostic and clinical implications. Best Pract Res Clin Endocrinol Metab. 2008 Dec; 22(6):955-69.Best Pract Res Clin Endocrinol Metab2008-12-01T00:00:002008Molecular pathology of thyroid cancer: diagnostic and clinical implications.19751238Negri JM, McMillin DW, Delmore J, Mitsiades N, Hayden P, Klippel S, Hideshima T, Chauhan D, Munshi NC, Buser CA, Pollard J, Richardson PG, Anderson KC, Mitsiades CSBritish journal of haematologyIn vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465. Br J Haematol. 2009 Dec; 147(5):672-6.Br J Haematol2009-09-14T00:00:002009In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465.21828154Mitsiades N, Chew SA, He B, Riechardt AI, Karadedou T, Kotoula V, Poulaki VInvestigative ophthalmology & visual scienceGenotype-dependent sensitivity of uveal melanoma cell lines to inhibition of B-Raf, MEK, and Akt kinases: rationale for personalized therapy. Invest Ophthalmol Vis Sci. 2011 Sep 14; 52(10):7248-55.Invest Ophthalmol Vis Sci2011-09-14T00:00:002011Genotype-dependent sensitivity of uveal melanoma cell lines to inhibition of B-Raf, MEK, and Akt kinases: rationale for personalized therapy.Authorship 8821069Authorship 884123229332125Kaochar S, Dong J, Torres M, Rajapakshe K, Nikolos F, Davis CM, Ehli EA, Coarfa C, Mitsiades N, Poulaki VInvestigative ophthalmology & visual scienceICG-001 Exerts Potent Anticancer Activity Against Uveal Melanoma Cells. Invest Ophthalmol Vis Sci. 2018 01 01; 59(1):132-143.Invest Ophthalmol Vis Sci2018-01-01T00:00:002018ICG-001 Exerts Potent Anticancer Activity Against Uveal Melanoma Cells.29605661Kaochar S, Mitsiades NTrends in endocrinology and metabolism: TEMA Novel Mechanism to Drive Castration-Resistant Prostate Cancer. Trends Endocrinol Metab. 2018 06; 29(6):366-368.Trends Endocrinol Metab2018-03-28T00:00:002018A Novel Mechanism to Drive Castration-Resistant Prostate Cancer.true1Assistant ProfessorAssistant Professortrue1ProfessorProfessorAuthorship 1071091D009101Disorders36221390.432212Multiple MyelomaD013964Disorders36218630.446935Thyroid NeoplasmsD011944Chemicals & Drugs2908750.646186Receptors, AndrogenD011471Disorders75157520.293197Prostatic NeoplasmsAuthorship 107061Authorship 934620330254080Thorek DLJ, Ku AT, Mitsiades N, Veach D, Watson PA, Metha D, Strand SE, Sharma SK, Lewis JS, Abou DS, Lilja HG, Larson SM, McDevitt MR, Ulmert DClinical cancer research : an official journal of the American Association for Cancer ResearchHarnessing Androgen Receptor Pathway Activation for Targeted Alpha Particle Radioimmunotherapy of Breast Cancer. Clin Cancer Res. 2019 01 15; 25(2):881-891.Clin Cancer Res2018-09-25T00:00:002018Harnessing Androgen Receptor Pathway Activation for Targeted Alpha Particle Radioimmunotherapy of Breast Cancer.2020-07-31NIHMITSIADES, NICHOLAS2015-08-01REGULATION OF UVEAL MELANOMA CELL FATE BY THE PKC PATHWAY VIA MITFR01CA1933212023-06-30NIHMITSIADES, NICHOLAS2018-09-20Minority PDX Development and Trial Center: Baylor College of Medicine and MD Anderson Cancer Center Collaboration on Mechanistic Studies to Dissect and Combat Health Disparities in CancerU54CA233223Principal InvestigatorPrincipal InvestigatorAuthorship 1052807Department of MedicineDepartment of Molecular & Cellular BiologyDepartment of Pathology & ImmunologyMedicine-EndocrinologyMedicine-GeriatricsMolecular & Cellular BiologyPathologyBaylor College of MedicineCRISTIANCOARFACRISTIAN COARFA0.000000000000000.000000000000001149COARFA, CRISTIANAssociate ProfessorMICHAELLIEBSCHNERMICHAEL LIEBSCHNER0.000000000000000.000000000000001464LIEBSCHNER, MICHAELAssociate ProfessorMARGARETSPITZMARGARET SPITZ0.000000000000000.000000000000001692SPITZ, MARGARETProfessor Emeritus3.228290.00640737591research areas1.356180.031622942coauthor of119.87122.088760similar to11112selected publicationsCHARLESMINARDCHARLES MINARD0.000000000000000.000000000000004376MINARD, CHARLESAssociate ProfessorYANHONGLIUL6dhsUXFI4a7Q4v4YANHONG LIU0.000000000000000.000000000000004010LIU, YANHONGAssistant ProfessorAuthorship 1093121BERTO'MALLEYBERT O'MALLEY0.000000000000000.000000000000002464O'MALLEY, BERTDistinguished Service ProfessorMICHAELITTMANNMICHAEL ITTMANN0.000000000000000.000000000000002694ITTMANN, MICHAELProfessorAuthorship 1095141D064129Disorders1184130.694606Prostatic Neoplasms, Castration-ResistantAuthorship 128952123887973Mitsiades NCancer researchA road map to comprehensive androgen receptor axis targeting for castration-resistant prostate cancer. Cancer Res. 2013 Aug 01; 73(15):4599-605.Cancer Res2013-07-25T00:00:002013A road map to comprehensive androgen receptor axis targeting for castration-resistant prostate cancer.Authorship 9491052131198906Bader DA, Hartig SM, Putluri V, Foley C, Hamilton MP, Smith EA, Saha PK, Panigrahi A, Walker C, Zong L, Martini-Stoica H, Chen R, Rajapakshe K, Coarfa C, Sreekumar A, Mitsiades N, Bankson JA, Ittmann MM, O'Malley BW, Putluri N, McGuire SENature metabolismMitochondrial pyruvate import is a metabolic vulnerability in androgen receptor-driven prostate cancer. Nat Metab. 2019 01; 1(1):70-85.Nat Metab2018-11-19T00:00:002018Mitochondrial pyruvate import is a metabolic vulnerability in androgen receptor-driven prostate cancer.Authorship 1116635Authorship 1118307Authorship 952961231360645Kaochar S, Mitsiades NTranslational cancer researchMultimodal action of ONECUT2 in driving neuroendocrine prostate cancer. Transl Cancer Res. 2019 Mar; 8(Suppl 2):S198-S203.Transl Cancer Res2019-03-01T00:00:002019Multimodal action of ONECUT2 in driving neuroendocrine prostate cancer.Authorship 9548641431481421Geng C, Rajapakshe K, Shah SS, Shou J, Eedunuri VK, Foley C, Fiskus W, Rajendran M, Chew SA, Zimmermann M, Bond R, He B, Coarfa C, Mitsiades NCancer researchCorrection: Androgen Receptor Is the Key Transcriptional Mediator of the Tumor Suppressor SPOP in Prostate Cancer. Cancer Res. 2019 Sep 01; 79(17):4552.Cancer Res2019-09-01T00:00:002019Correction: Androgen Receptor Is the Key Transcriptional Mediator of the Tumor Suppressor SPOP in Prostate Cancer.Authorship 1125757true1Distinguished Service ProfessorDistinguished Service ProfessorAuthorship 1089851Authorship 1135391Authorship 1132027true1Assistant ProfessorAssistant ProfessorAuthorship 9877761532314924Wu F, Hua Y, Kaochar S, Nie S, Lin YL, Yao Y, Wu J, Wu X, Fu X, Schiff R, Davis CM, Robertson M, Ehli EA, Coarfa C, Mitsiades N, Song YJournal of medicinal chemistryDiscovery, Structure-Activity Relationship, and Biological Activity of Histone-Competitive Inhibitors of Histone Acetyltransferases P300/CBP. J Med Chem. 2020 05 14; 63(9):4716-4731.J Med Chem2020-04-21T00:00:002020Discovery, Structure-Activity Relationship, and Biological Activity of Histone-Competitive Inhibitors of Histone Acetyltransferases P300/CBP.Authorship 998214932859606Dhimolea E, de Matos Simoes R, Kansara D, Weng X, Sharma S, Awate P, Liu Z, Gao D, Mitsiades N, Schwab JH, Chen Y, Jeselsohn R, Culhane AC, Brown M, Georgakoudi I, Mitsiades CSCancer researchPleiotropic Mechanisms Drive Endocrine Resistance in the Three-Dimensional Bone Microenvironment. Cancer Res. 2021 01 15; 81(2):371-383.Cancer Res2020-08-28T00:00:002020Pleiotropic Mechanisms Drive Endocrine Resistance in the Three-Dimensional Bone Microenvironment.true1Associate ProfessorAssociate ProfessorAuthorship 1007737233358624Kaochar S, Mitsiades NEuropean urologyRe: Umang Swami, Pedro Isaacsson Velho, Roberto Nussenzveig, et al. Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer. Eur Urol 2020;78:652-6: Can Mutant SPOP Become an Actionable Biomarker for Precision Oncology Management of Prostate Cancer? Eur Urol. 2021 03; 79(3):e91-e93.Eur Urol2020-12-25T00:00:002020Re: Umang Swami, Pedro Isaacsson Velho, Roberto Nussenzveig, et al. Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer. Eur Urol 2020;78:652-6: Can Mutant SPOP Become an Actionable Biomarker for Precision Oncology Management of Prostate Cancer?Authorship 1166041Authorship 1021195134128827Mitsiades N, Kaochar SEndocrine-related cancerAndrogen receptor signaling inhibitors: post-chemotherapy, pre-chemotherapy and now in castration-sensitive prostate cancer. Endocr Relat Cancer. 2021 07 15; 28(8):T19-T38.Endocr Relat Cancer2021-07-15T00:00:002021Androgen receptor signaling inhibitors: post-chemotherapy, pre-chemotherapy and now in castration-sensitive prostate cancer.true1Associate ProfessorAssociate ProfessorAuthorship 10314171934636746Kaochar S, Rusin A, Foley C, Rajapakshe K, Robertson M, Skapura D, Mason C, Berman De Ruiz K, Tyryshkin AM, Deng J, Shin JN, Fiskus W, Dong J, Huang S, Navone NM, Davis CM, Ehli EA, Coarfa C, Mitsiades NEndocrine-related cancerInhibition of GATA2 in prostate cancer by a clinically available small molecule. Endocr Relat Cancer. 2021 11 24; 29(1):15-31.Endocr Relat Cancer2021-11-24T00:00:002021Inhibition of GATA2 in prostate cancer by a clinically available small molecule.Authorship 10326621434711608Gou X, Anurag M, Lei JT, Kim BJ, Singh P, Seker S, Fandino D, Han A, Rehman S, Hu J, Korchina V, Doddapaneni H, Dobrolecki LE, Mitsiades N, Lewis MT, Welm AL, Li S, Lee AV, Robinson DR, Foulds CE, Ellis MJCancer researchTranscriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast Cancer. Cancer Res. 2021 12 15; 81(24):6259-6272.Cancer Res2021-10-28T00:00:002021Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast Cancer.ELIZABETHBRIERREELIZABETH BRIERRE0.000000000000000.000000000000007014BRIERRE, ELIZABETHAssistant ProfessorAuthorship 137943true1Associate ProfessorAssociate ProfessorAuthorship 1039427335122875Lowder D, Rizwan K, McColl C, Paparella A, Ittmann M, Mitsiades N, Kaochar SCancer lettersRacial disparities in prostate cancer: A complex interplay between socioeconomic inequities and genomics. Cancer Lett. 2022 04 10; 531:71-82.Cancer Lett2022-02-03T00:00:002022Racial disparities in prostate cancer: A complex interplay between socioeconomic inequities and genomics.Authorship 10445612235475145Koc S, Lloyd MW, Grover JW, Xiao N, Seepo S, Subramanian SL, Ray M, Frech C, DiGiovanna J, Webster P, Neuhauser S, Srivastava A, Woo XY, Sanderson BJ, White B, Lott P, Dobrolecki LE, Dowst H, PDXNet Consortium , Evrard YA, Wallace TA, Moscow JA, Doroshow JH, Mitsiades N, Kaochar S, Pan CX, Chen MS, Carvajal-Carmona L, Welm AL, Welm BE, Lewis MT, Govindan R, Ding L, Li S, Herlyn M, Davies MA, Roth J, Meric-Bernstam F, Robinson PN, Bult CJ, Davis-Dusenbery B, Dean DA, Chuang JHNAR cancerPDXNet portal: patient-derived Xenograft model, data, workflow and tool discovery. NAR Cancer. 2022 Jun; 4(2):zcac014.NAR Cancer2022-04-22T00:00:002022PDXNet portal: patient-derived Xenograft model, data, workflow and tool discovery.Authorship 1048917735731919Berchuck JE, Adib E, Abou Alaiwi S, Dash AK, Shin JN, Lowder D, McColl C, Castro P, Carelli R, Benedetti E, Deng J, Robertson M, Baca SC, Bell C, McClure HM, El Zarif T, Davidsohn MP, Lakshminarayanan G, Rizwan K, Skapura DG, Grimm SL, Davis CM, Ehli EA, Kelleher KM, Seo JH, Mitsiades N, Coarfa C, Pomerantz MM, Loda M, Ittmann M, Freedman ML, Kaochar SCancer researchThe Prostate Cancer Androgen Receptor Cistrome in African American Men Associates with Upregulation of Lipid Metabolism and Immune Response. Cancer Res. 2022 08 16; 82(16):2848-2859.Cancer Res2022-08-16T00:00:002022The Prostate Cancer Androgen Receptor Cistrome in African American Men Associates with Upregulation of Lipid Metabolism and Immune Response.Authorship 12081413true1Adjunct Associate ProfessorAdjunct Associate ProfessorAuthorship 163951true1Professor EmeritusProfessor EmeritusAuthorship 189462true1ProfessorProfessortrue1Associate ProfessorAssociate Professortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1Assistant ProfessorAssistant Professortrue1ProfessorProfessorAuthorship 245243Authorship 249899Authorship 235581Authorship 266369Authorship 270651Authorship 327241824359151Kaushik AK, Vareed SK, Basu S, Putluri V, Putluri N, Panzitt K, Brennan CA, Chinnaiyan AM, Vergara IA, Erho N, Weigel NL, Mitsiades N, Shojaie A, Palapattu G, Michailidis G, Sreekumar AJournal of proteome researchMetabolomic profiling identifies biochemical pathways associated with castration-resistant prostate cancer. J Proteome Res. 2014 Feb 07; 13(2):1088-100.J Proteome Res2013-12-31T00:00:002013Metabolomic profiling identifies biochemical pathways associated with castration-resistant prostate cancer.Authorship 37121Authorship 2970715Authorship 13958111Authorship 3033411Authorship 448423Authorship 143143724595385Cerne JZ, Hartig SM, Hamilton MP, Chew SA, Mitsiades N, Poulaki V, McGuire SEInvestigative ophthalmology & visual scienceProtein kinase C inhibitors sensitize GNAQ mutant uveal melanoma cells to ionizing radiation. Invest Ophthalmol Vis Sci. 2014 Apr 07; 55(4):2130-9.Invest Ophthalmol Vis Sci2014-04-07T00:00:002014Protein kinase C inhibitors sensitize GNAQ mutant uveal melanoma cells to ionizing radiation.Authorship 546255Authorship 381331Authorship 5767617Authorship 1470561424874954Feng Q, Zhang Z, Shea MJ, Creighton CJ, Coarfa C, Hilsenbeck SG, Lanz R, He B, Wang L, Fu X, Nardone A, Song Y, Bradner J, Mitsiades N, Mitsiades CS, Osborne CK, Schiff R, O'Malley BWCell researchAn epigenomic approach to therapy for tamoxifen-resistant breast cancer. Cell Res. 2014 Jul; 24(7):809-19.Cell Res2014-05-30T00:00:002014An epigenomic approach to therapy for tamoxifen-resistant breast cancer.Authorship 5919514Authorship 602967Authorship 612071Authorship 634532Authorship 46847Authorship 53751Authorship 567708Authorship 829167Authorship 832949Authorship 600352Authorship 596081Authorship 59858Authorship 850681Authorship 1518371425274033Geng C, Rajapakshe K, Shah SS, Shou J, Eedunuri VK, Foley C, Fiskus W, Rajendran M, Chew SA, Zimmermann M, Bond R, He B, Coarfa C, Mitsiades NCancer researchAndrogen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer. Cancer Res. 2014 Oct 01; 74(19):5631-43.Cancer Res2014-10-01T00:00:002014Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer.Authorship 614528Authorship 630001Authorship 640621Authorship 637471Authorship 676613Authorship 6794112Authorship 687081Authorship 674451Authorship 987892Authorship 993901Authorship 708171Authorship 721011Authorship 740791Authorship 7359410Authorship 7452817Authorship 766241Authorship 790551Authorship 772552Authorship 15542427